Legend Biotech (LEGN): Can the Stock Reach $40 From Current Levels?
Key Takeaways
- Selected stock price target: $40, which sits just above LEGN’s 52-week high of $38.35 and implies nearly double the recent price near $20.60.
- Strongest bullish factors: accelerating Carvykti sales, the first quarter of company-wide profitability, and promising early in vivo CAR-T data.
- Biggest obstacles: CEO departure, reduced merger-and-acquisition optionality, intensifying competition, and recent analyst target cuts.
- Key technical levels: support near $20.50 and $19, with resistance around $23, $28–$29, and the prior high near $38.35 before any test of $40.
- Analyst view: targets range from $24 to $78, with Oppenheimer’s reduced target at $40 and the broader consensus average still above $50.
- Key takeaway: $40 is ambitious but not impossible; it would likely require clear new leadership, stronger Carvykti momentum, and fresh pipeline validation.
Why the $40 Level Matters
The $40 stock price target is not arbitrary. Oppenheimer recently cut its LEGN target to $40 from $75 while downgrading the stock to Market Perform, keeping the round-number level in public market discussion. Because LEGN’s 52-week high is $38.35, reaching $40 would require clearing the stock’s prior peak and establishing a new uptrend. For a stock trading near $20.60, that is a major technical and psychological hurdle rather than a routine extension.
Recent Market Position
LEGN closed the prior session at $21.83 after a strong earnings-driven gain, but the latest session brought renewed pressure. TD Cowen lowered its target to $24 from $29, and Oppenheimer’s downgrade underscored concerns about strategy and competition. The stock has had a volatile year: it rallied toward the upper $30s in June before a discounted share offering, a CEO departure, and competitive fears erased those gains. LEGN now carries a market capitalization near $3.9 billion and remains far below its 52-week high.
What Could Drive the Next Leg Higher
The fundamental case for a recovery toward $40 is grounded in improving commercial execution. In the second quarter, LEGN reported adjusted earnings of $0.09 per share, above the $0.07 consensus, while revenue rose 51.9% year over year to $387.5 million. Management highlighted roughly $657 million in worldwide net trade sales for Carvykti, up about 50%, and said the company achieved its first quarter of company-wide profitability on both IFRS and adjusted bases.
Beyond Carvykti, Legend Biotech’s in vivo CAR-T program offers a potential second growth engine. Early Phase 1 data in B-cell non-Hodgkin lymphoma showed all six treated patients responded, with five complete responses. That level of early efficacy has kept long-term pipeline enthusiasm alive even as sentiment has deteriorated. A strengthened balance sheet from the recent capital raise also gives the company room to fund additional development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Prevent the Move
The obstacles are equally significant. The departure of CEO Ying Huang has increased strategic uncertainty at a delicate commercial moment. Oppenheimer also pointed to Johnson & Johnson (NYSE: JNJ) partnering with Sail Biomedicines, which removes what many investors viewed as the most likely near-term acquisition scenario for LEGN.
Competition is intensifying. Gilead Sciences’ anitocel is moving toward commercialization, while IQVIA data cited by analysts suggested softer Carvykti sales trends and stronger uptake for competing therapies. The June equity offering, priced at a double-digit discount, also weighed on investor confidence. Technically, LEGN must first reclaim supply zones near $23 and the $28–$29 area before a credible push toward the prior high near $38.35.
Analyst Price Targets and Technical Levels
Wall Street remains divided. Published 12-month targets span from $24 to $78, with the consensus average around $52 but the rating mix now closer to Hold than a clear Buy. That wide range reflects genuine uncertainty about leadership, commercial durability, and pipeline timelines. The $40 objective sits below the average target, but it would still require LEGN to outperform several recently reduced expectations.
On the chart, nearby support appears near $20.50 and then the $19 area, with the 52-week low at $16.24. Resistance is layered: the $23 zone is the first test, followed by $28–$29 and then the prior high near $38.35. A sustained move through those levels would be needed to make $40 realistic. From what I see, tracking these levels with additional technical overlays can help clarify the setup.
Final Assessment
Reaching $40 appears ambitious from a base near $20.60, because it would require a near-doubling and a new 52-week high. The strongest arguments for the move are accelerating Carvykti revenue, the company’s first quarterly profitability, and an in vivo CAR-T pipeline with meaningful long-term optionality. The main risks are leadership uncertainty, competitive pressure, diminished M&A prospects, and the stock’s current position below multiple technical resistance zones. For $40 to become realistic, investors would likely need to see a credible new CEO, renewed Carvykti sales momentum, and additional validating data from the broader pipeline. Until then, the target remains a possible but demanding objective rather than a near-term expectation.
Monitoring Volatile Names with AI Daily Buy/Sell Signals
In my own research process, I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful for keeping an eye on stocks like LEGN. The tool uses artificial intelligence to scan thousands of securities and generate Buy, Sell, or Hold signals based on changing market conditions and technical behavior. For a name with this level of volatility, it can assist in identifying potential shifts in trend and monitoring positions without replacing broader fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for LEGN turns negative, indicating new downward trend
LEGN saw its Momentum Indicator move below the 0 level on October 08, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned negative. In 89 of the 100 cases, the stock moved further down in the following days. The odds of a decline are at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 57 cases where LEGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LEGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
LEGN broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LEGN entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LEGN's RSI Indicator exited the oversold zone, 33 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for LEGN just turned positive on September 24, 2026. Looking at past instances where LEGN's MACD turned positive, the stock continued to rise in 34 of 51 cases over the following month. The odds of a continued upward trend are 67%.
Following a +6.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where LEGN advanced for three days, in 174 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.946) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (2.478) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. LEGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LEGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications
Industry Biotechnology
Advertisement